#None #Norgine #Mavorixafor #WHIM syndrome

Norgine Applauds CHMP's Positive Opinion for Mavorixafor

Norgine B.V., a prominent player in the European specialty pharmaceutical market, is excited to announce a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This endorsement pertains to mavorixafor, aimed at treating WHIM syndrome in patients aged 12 and older. The anticipated approval would make mavorixafor the first authorized treatment for this rare disease in Europe.

Understanding WHIM Syndrome

WHIM syndrome, which stands for warts, hypogammaglobulinemia, infections, and myelokathexis, is an ultra-rare immunodeficiency disorder. This condition arises from a malfunction in the CXCR4 chemokine receptor, leading to an impaired release of white blood cells from the bone marrow. Consequently, patients experience reduced circulation of mature neutrophils and lymphocytes, rendering them more susceptible to severe infections.

Currently, there are no approved treatments for WHIM syndrome, making the positive CHMP opinion a significant breakthrough for patients and healthcare providers. This decision is backed by findings from the pivotal phase 3 clinical trial (4WHIM), which demonstrated the efficacy and safety of mavorixafor in patients with this condition.

Result of the Clinical Trials

The phase 3 trial involved a global, randomized, double-blind, placebo-controlled setup over 52 weeks, covering 31 diagnosed individuals. The results were promising, showcasing mavorixafor's capability to elevate the levels of circulating neutrophils and lymphocytes, thereby improving patients' immunity and quality of life.

CEO of Norgine, Janneke van der Kamp, expressed her enthusiasm regarding this regulatory milestone, highlighting Norgine's dedication to delivering innovative treatments to underserved populations.

Norgine's Role and Future Plans

Norgine has established a partnership with X4 Pharmaceuticals, wherein Norgine will oversee the commercial distribution of mavorixafor in Europe, Australia, and New Zealand post-approval. The agreement, initiated in January 2025, delegates marketing authorization rights in these territories to Norgine. X4 Pharmaceuticals is responsible for the manufacturing and supply of the medication, underpinning strong collaborative efforts in addressing the needs of WHIM syndrome patients.

Guided by a trust developed over years of service to healthcare professionals and patients, Norgine emphasizes its commitment to innovation. Their goal is not only to approve medications but also to enhance the lives of those suffering from rare diseases.

Conclusion

The CHMP's positive opinion is a pivotal step toward enhancing the treatment landscape for individuals with WHIM syndrome. Following a final decision from the European Commission expected in Q2 2026, mavorixafor could revolutionize how this challenging condition is managed. Norgine's relentless pursuit of excellence in medicine continues to transform lives, as they strive to provide solutions for those with unmet medical needs.